Induction of Immune Responses by DNA Vaccines Formulated with Dendrimer and Poly (Methyl Methacrylate) (PMMA) Nano-Adjuvants in BALB/c Mice Infected with Leishmania major

Authors

  • Fatemeh Tabatabaie Department of Parasitology and Mycology, Faculty of Medicine, Iran University of Medical Sciences, Tehran
  • Nasim Samarghandi Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan
  • Somayeh Zarrati Microbiology Department, Science & Research Branch, Islamic Azad University, Tehran
  • Fatemeh Maleki 4Department of Parasitology, Faculty of Para Medical Sciences, Iran University of Medical Sciences, Tehran
  • Mehdi Shafiee Ardestani Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran
  • Taher Elmi Department of Parasitology and Mycology, Faculty of Medicine, Iran University of Medical Sciences, Tehran
  • Sayed Hussain Mosawi Department of Biology and Microbiology, Faculty of Medical Technology. Khatam Al Nabieen University, Kabul

DOI:

https://doi.org/10.3889/oamjms.2018.061

Keywords:

PMMA, Dendrimer, Leishmaniasis, TSA

Abstract

BACKGROUND: Leishmaniasis is a parasitic disease induced by a protozoan from the genus Leishmania. No effective vaccine has yet been developed against the disease.

AIM: In this work, two nano-vaccines, TSA recombinant plasmid and dendrimer and poly (methyl methacrylate) (PMMA) nanoparticles (as adjuvants), were designed and tested for their immunogenicity in BALB/c mice.

METHODS: After the plasmid construction and preparation of adjuvants, three intramuscular injections of the nano-vaccines (100 µg) and the recombinant TSA protein (20 µg) were subcutaneously performed. Eventually, the challenged animals were infected with the parasites (1*106 promastigotes). After the last injections of the nano-vaccines, the responses of their antibody subclasses and cytokines were assessed via ELISA method before and after the challenge.

RESULTS: This study revealed that the new nano-vaccines were strong and effective in inducing specific antibody and cellular responses and reducing the parasite burden in the spleen compared to the control groups of Leishmania major-infected BALB/c mice.

CONCLUSION: Based on the results, we can suggest that the formulated vaccines are suitable candidates for further studies in the field of leishmaniasis control.
 

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Zarrati S, Mahdavi M, Tabatabaie F, Immune responses in DNA vaccine formulated with PMMA following immunization and after challenge with Leishmania major. J Parasit Dis. 2014:1-9.

Zarrati S, Maleki F, Mahdavi M, Khabaz zadeh Tehrani N, Abrehdari Tafreshi Z, Asadi AH, Tabatabaie F. Humoral immune responses in DNA vaccine formulated with poly [methyl methacrylate] against Leishmania major, India Journal of Entomology and Zoology Studies. 2014; 2(5): 201-206.

Mutiso JM, Macharia JC, Gicheru MM. A review of adjuvants for Leishmania vaccine candidates. J Biomed Res. 2010; 24:16–25. https://doi.org/10.1016/S1674-8301(10)60004-8

O'Hagan DT. Methods in molecular medicine, vaccine adjuvants: preparation methods and research protocols. Humana Press, Totowa, 2000. https://doi.org/10.1385/1592590837

Scott RWJ, Wilson OM, Crooks RM. Synthesis, Characterization, and Applications of Dendrimer-Encapsulated Nanoparticles. J Phys Chem B. 2005; 109(2):692–704. https://doi.org/10.1021/jp0469665 PMid:16866429

Hariria, I, Shafiee-Alavidjeh M, Khorramizadeh MR, Shafiee-Ardestani M, Zarei-Ghane Z, Namazi H. Anionic linear-globular dendrimer-cis-platinum [II] conjugates promote cytotoxicity in vitro against different cancer cell lines. Int J Nanomedicine. 2010; 5:63–75. https://doi.org/10.2147/IJN.S8595

Mutiso JM, Macharia JC, Gicheru MM. A review of adjuvants for Leishmania vaccine candidates. J Biomed Res. 2010; 24:16–25. https://doi.org/10.1016/S1674-8301(10)60004-8

Ghaffarifar F, Tabatabaie F, Sharifi Z, Dalimiasl A, Zahir Hassan M, Mahdavi M. Cloning of a Recombinant Plasmid Encoding Thiol-Specific Antioxidant Antigen [TSA] Gene of Leishmania major and Expression in the Chinese Hamster Ovary Cell Line. Malays J Med Sci. 2012; 19(1): 15-19.

Sasaki S, Takeshita F, Xin KQ, Ishii N, Okuda K. Adjuvant formulations and delivery systems for DNA vaccines. Methods. 2003; 31:243–254. https://doi.org/10.1016/S1046-2023(03)00140-3

Ahmed SB, Touihri L, Chtourou Y, Dellagi K, Bahloul C. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania [Leishmania] major antigens confers full protection in BALB/c mice. Vaccine. 2009; 27:99–106. https://doi.org/10.1016/j.vaccine.2008.10.013 PMid:18951941

Rafati S, Zahedifard F, Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine. 2006; 24:2169–2175. https://doi.org/10.1016/j.vaccine.2005.11.011 PMid:16325969

Tabatabaie F, Ghaffarifar F, Sharifi Z, Dalimi A, Zavaran Hoseini A. Cloning and sequencing of Leishmania major thiol- specific antioxidant antigen [TSA] gene. Iranian J Parasitol. 2007; 2:30–41.

Ahmed SB, Bahloul C, Robbana C, Askri S, Dellagi K. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major. Vaccine. 2004; 22:1631–1639. https://doi.org/10.1016/j.vaccine.2003.10.046 PMid:15068845

Ivory C, Chadee K. DNA vaccines: designing strategies against parasitic infections. Genet Vaccines Ther. 2004; 2:17. https://doi.org/10.1186/1479-0556-2-17 PMid:15579202 PMCid:PMC544584

Badiee A, Heravi Shargh V, Khamesipour A, Jaafari MR. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends. Vaccine. 2013; 31:735–749. https://doi.org/10.1016/j.vaccine.2012.11.068 PMid:23219436

Alavidjeh MS, Haririan I, Khorramizadeh MR, Ghane ZZ, Ardestani MS, Namazi H. Anionic linear-globular dendrimers: biocompatible hybrid materials with potential uses in nanomedicine. J Mater Sci-Mater. 2010; 21(4):1121-1133. https://doi.org/10.1007/s10856-009-3978-8 PMid:20082119

Yallapu MM, Jaggi M, Chauhan S. Curcumin nanoformulations: a future nanomedicine for cancer. Drug discovery today. 2012; 17(1):71-80. https://doi.org/10.1016/j.drudis.2011.09.009 PMid:21959306 PMCid:PMC3259195

Emanuele AD, Attwood D. Dendrimer–drug interactions. Adv. Drug Deliv Rev. 2005; 57: 2147–2162. https://doi.org/10.1016/j.addr.2005.09.012 PMid:16310283

Mohammadi E, Amanlou M, Sadat Ebrahimi SE, Pirali Hamedani M, Mahrooz A, Mehravi B, et al. Cellular uptake, imaging and pathotoxicological studies of a novel Gd[III]–DO3A-butrol nanoformulation. 2014; 4:45984–45994.

Izanloo H, Ahmadi Jebelli M, Nazari Sh, Safavi N, Tashauoei HR, Majidi GH, et. Studying the antibacterial effect of Polyamidoamine-G4 Dendrimer on some of the gram-negative and gram-positive bacteria. Arak Medical University Journal [AMUJ]. 2014; 17(90):1-10.

Kreuter J, Mauler R, Gruschkau H, Speiser PP. The use of new polymethylmethacrylate adjuvants for split influenza vaccines. Exp Cell Biol. 1976; 44:12–19. https://doi.org/10.1159/000162849

Voltan R, Castaldello A, Brocca-Cofano E, Altavilla G, Caputo A, Laus M, et al. Preparation and characterization of innovative protein-coated poly[methylmethacrylate] core-shell nanoparticles for vaccine purposes. Pharm Res. 2007; 24:1870–1882. https://doi.org/10.1007/s11095-007-9310-8 PMid:17476465

Danesh-Bahreini MA, Shokri J, Samiei A, Kamali-Sarvestani E, Barzegar-Jalali M, Mohammadi-Samani S. Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice. Int J Nanomed. 2011; 6:835–842. PMid:21589651 PMCid:PMC3090280

Stieneker F, Kersten G, van Bloois L, Crommelin DJ, Hem SL, Lower J, et al. Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. Vaccine. 1995; 13:45–53. https://doi.org/10.1016/0264-410X(95)80010-B

Emanuele AD, Attwood D. Dendrimer–drug interactions. Adv Drug Deliv Rev. 2005; 57: 2147–2162. nhttps://doi.org/10.1016/j.addr.2005.09.012 PMid:16310283

Campos-Neto A, et al. What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery? Brazilian J Med Biol Res = Revista brasileira de pesquisas medicas e biologicas/Sociedade Brasileira de Biofisica. 2005; 38:979–984.

Campos-Neto A, Webb JR, Greeson K, Coler RN, Skeiky YA, Reed SG. Vaccination with plasmid DNA encoding TSA/ LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun. 2002; 70:2828–2836. https://doi.org/10.1128/IAI.70.6.2828-2836.2002 PMid:12010969 PMCid:PMC128002

Tewary P, Jain M, Sahani MH, Saxena S, Madhubala RA. Heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis. J Infect Dis. 2005; 191:2130–2137. https://doi.org/10.1086/430348 PMid:15898000

Published

2018-01-27

How to Cite

1.
Tabatabaie F, Samarghandi N, Zarrati S, Maleki F, Ardestani MS, Elmi T, Mosawi SH. Induction of Immune Responses by DNA Vaccines Formulated with Dendrimer and Poly (Methyl Methacrylate) (PMMA) Nano-Adjuvants in BALB/c Mice Infected with Leishmania major. Open Access Maced J Med Sci [Internet]. 2018 Jan. 27 [cited 2024 Nov. 4];6(2):229-36. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2018.061

Issue

Section

A - Basic Science